ArticleGlobal epidemiology2026
Measles incidence and measles-containing vaccine coverage in Chereponi District, Ghana, 2019-2024: A retrospective analysis of routine surveillance and immunization data.
Article in Global epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To describe temporal patterns in measles occurrence and measles-containing vaccine (MCV) coverage in Chereponi District, Ghana, from 2019 to 2024. Methods: A retrospective descriptive study analysed routine SORMAS and DHIMS2 data from 2019 to 2024. Annual suspected and laboratory-confirmed measles incidence, MCV1 and MCV2 coverage, and MCV1-MCV2 dropout were summarized descriptively. Results: During 2019-2024, 167 suspected measles cases were reported through district surveillance, of which 31 (18.6%) were laboratory-confirmed. Children aged 0-4 years accounted for 66.9% of suspected cases with recorded age, while 5-9-year-olds accounted for 23.4%. Suspected notifications peaked in 2022, whereas laboratory-confirmed incidence was highest in 2023. MCV1 reached 95% only in 2020, while MCV2 remained below 90% in four of six years. MCV1-MCV2 dropout exceeded 10% in four years and declined to 8.6% in 2024. Conclusion: Chereponi experienced substantial year-to-year variation in measles occurrence amid inconsistent two-dose MCV coverage and periods of high dropout. Strengthening routine immunization, defaulter tracing, outreach, denominator validation, and case-based surveillance remains essential for measles elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.